Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
June 27, 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US...
Verona Pharma to Present at Jefferies Healthcare Conference
May 24, 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023 02:00 ET
|
Verona Pharma plc
NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support...
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
May 02, 2023 02:00 ET
|
Verona Pharma plc
12 Abstracts and one Symposium further support potential of ensifentrine,a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON...
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
April 25, 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
April 10, 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 07, 2023 02:00 ET
|
Verona Pharma plc
Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST /...
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
February 21, 2023 02:00 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
December 20, 2022 02:00 ET
|
Verona Pharma plc
Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission...
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD
December 19, 2022 16:01 ET
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...